Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302510 | 1.00 | PYGB (0.48) | PYGBGAAMAPK1PRKCACA12 | |
| SCHEMBL12198733 | 1.00 | PYGB (0.48) | PYGBGAAMAPK1PRKCACA12 | |
| SCHEMBL2305282 | 0.98 | PYGB (0.47) | PYGBGAAMAPK1PRKCAGJB2 | |
| SCHEMBL3878575 | 0.98 | PYGB (0.47) | PYGBGAAMAPK1PRKCAGJB2 | |
| SCHEMBL10301424 | 0.85 | LGALS8 (0.53) | MAPK1GJB2 | |
| SCHEMBL12198736 | 0.85 | LGALS8 (0.53) | MAPK1GJB2 | |
| SCHEMBL27806724 | 0.82 | SELP (0.45) | PYGBGAACA12CA1CA2 | |
| SCHEMBL2794643 | 0.82 | SELP (0.45) | PYGBGAACA12CA1CA2 | |
| SCHEMBL2792078 | 0.82 | SELP (0.45) | PYGBGAACA12CA1CA2 | |
| SCHEMBL21391551 | 0.81 | PYGB (0.40) | PYGBGAACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350108-B1 | C-GLYCOSIDE COMPOUNDS, AND METHOD FOR PREPARING C-GLYCOSIDE COMPOUNDS | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE RENNES (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8569467-B2 | C-glycoside compounds, and method for preparing C-glycoside compounds | ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE RENNES (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20110245490-A1 | C-GLYCOSIDE COMPOUNDS, AND METHOD FOR PREPARING C-GLYCOSIDE COMPOUNDS | ARMOR PROTEINES (FR) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245490-A1 | C-GLYCOSIDE COMPOUNDS, AND METHOD FOR PREPARING C-GLYCOSIDE COMPOUNDS | FUT5, FUT6, CSGALNACT1 | PYGB 750/4885GAA 778/4885MAPK1 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.